Brigatinib versus crizotinib in ALK-positive non-small-cell lung cancer

D.R. Camidge; H.R. Kim; M.-J. Ahn; J.C.-H. Yang; J.-Y. Han; J.-S. Lee; M.J. Hochmair; J.Y.-C. Li; G.-C. Chang; K.H. Lee; C. Gridelli; A. Delmonte; R. Garcia Campelo; D.-W. Kim; A. Bearz; F. Griesinger; A. Morabito; E. Felip; R. Califano; S. Ghosh; A. Spira; S.N. Gettinger; M. Tiseo; N. Gupta; J. Haney; D. Kerstein; S. Popat

doi:10.1056/NEJMoa1810171

Brigatinib versus crizotinib in ALK-positive non-small-cell lung cancer

D.R. Camidge, H.R. Kim, M.-J. Ahn, J.C.-H. Yang, J.-Y. Han, J.-S. Lee, M.J. Hochmair, J.Y.-C. Li, G.-C. Chang, K.H. Lee, C. Gridelli, A. Delmonte, R. Garcia Campelo, D.-W. Kim, A. Bearz, F. Griesinger, A. Morabito, E. Felip, R. Califano, S. GhoshA. Spira, S.N. Gettinger, M. Tiseo, N. Gupta, J. Haney, D. Kerstein, S. Popat

Research output: Contribution to journal › Article

Original language	Italian
Pages (from-to)	2027-2039
Number of pages	13
Journal	New England Journal of Medicine
Volume	379
Issue number	21
DOIs	https://doi.org/10.1056/NEJMoa1810171
Publication status	Published - 2018

Access to Document

10.1056/NEJMoa1810171

https://www.scopus.com/inward/record.uri?eid=2-s2.0-85054414228&doi=10.1056%2fNEJMoa1810171&partnerID=40&md5=0fb0cc6c051ffaab6344f6c05ee65589

Cite this

Camidge, D. R., Kim, H. R., Ahn, M-J., Yang, JC-H., Han, J-Y., Lee, J-S., Hochmair, M. J., Li, JY-C., Chang, G-C., Lee, K. H., Gridelli, C., Delmonte, A., Garcia Campelo, R., Kim, D-W., Bearz, A., Griesinger, F., Morabito, A., Felip, E., Califano, R., ... Popat, S. (2018). Brigatinib versus crizotinib in ALK-positive non-small-cell lung cancer. New England Journal of Medicine, 379(21), 2027-2039. https://doi.org/10.1056/NEJMoa1810171

Brigatinib versus crizotinib in ALK-positive non-small-cell lung cancer. / Camidge, D.R.; Kim, H.R.; Ahn, M.-J.; Yang, J.C.-H.; Han, J.-Y.; Lee, J.-S.; Hochmair, M.J.; Li, J.Y.-C.; Chang, G.-C.; Lee, K.H.; Gridelli, C.; Delmonte, A.; Garcia Campelo, R.; Kim, D.-W.; Bearz, A.; Griesinger, F.; Morabito, A.; Felip, E.; Califano, R.; Ghosh, S.; Spira, A.; Gettinger, S.N.; Tiseo, M.; Gupta, N.; Haney, J.; Kerstein, D.; Popat, S.

In: New England Journal of Medicine, Vol. 379, No. 21, 2018, p. 2027-2039.

Research output: Contribution to journal › Article

Camidge, DR, Kim, HR, Ahn, M-J, Yang, JC-H, Han, J-Y, Lee, J-S, Hochmair, MJ, Li, JY-C, Chang, G-C, Lee, KH, Gridelli, C, Delmonte, A, Garcia Campelo, R, Kim, D-W, Bearz, A, Griesinger, F, Morabito, A, Felip, E, Califano, R, Ghosh, S, Spira, A, Gettinger, SN, Tiseo, M, Gupta, N, Haney, J, Kerstein, D & Popat, S 2018, 'Brigatinib versus crizotinib in ALK-positive non-small-cell lung cancer', New England Journal of Medicine, vol. 379, no. 21, pp. 2027-2039. https://doi.org/10.1056/NEJMoa1810171

Camidge, D.R. ; Kim, H.R. ; Ahn, M.-J. ; Yang, J.C.-H. ; Han, J.-Y. ; Lee, J.-S. ; Hochmair, M.J. ; Li, J.Y.-C. ; Chang, G.-C. ; Lee, K.H. ; Gridelli, C. ; Delmonte, A. ; Garcia Campelo, R. ; Kim, D.-W. ; Bearz, A. ; Griesinger, F. ; Morabito, A. ; Felip, E. ; Califano, R. ; Ghosh, S. ; Spira, A. ; Gettinger, S.N. ; Tiseo, M. ; Gupta, N. ; Haney, J. ; Kerstein, D. ; Popat, S. / Brigatinib versus crizotinib in ALK-positive non-small-cell lung cancer. In: New England Journal of Medicine. 2018 ; Vol. 379, No. 21. pp. 2027-2039.

@article{8151e3e371d04fd7bab6593cab405c2a,

title = "Brigatinib versus crizotinib in ALK-positive non-small-cell lung cancer",

author = "D.R. Camidge and H.R. Kim and M.-J. Ahn and J.C.-H. Yang and J.-Y. Han and J.-S. Lee and M.J. Hochmair and J.Y.-C. Li and G.-C. Chang and K.H. Lee and C. Gridelli and A. Delmonte and {Garcia Campelo}, R. and D.-W. Kim and A. Bearz and F. Griesinger and A. Morabito and E. Felip and R. Califano and S. Ghosh and A. Spira and S.N. Gettinger and M. Tiseo and N. Gupta and J. Haney and D. Kerstein and S. Popat",

note = "Cited By :15 Export Date: 4 February 2019",

year = "2018",

doi = "10.1056/NEJMoa1810171",

language = "Italian",

volume = "379",

pages = "2027--2039",

journal = "New England Journal of Medicine",

issn = "0028-4793",

publisher = "Massachussetts Medical Society",

number = "21",

}

TY - JOUR

T1 - Brigatinib versus crizotinib in ALK-positive non-small-cell lung cancer

AU - Camidge, D.R.

AU - Kim, H.R.

AU - Ahn, M.-J.

AU - Yang, J.C.-H.

AU - Han, J.-Y.

AU - Lee, J.-S.

AU - Hochmair, M.J.

AU - Li, J.Y.-C.

AU - Chang, G.-C.

AU - Lee, K.H.

AU - Gridelli, C.

AU - Delmonte, A.

AU - Garcia Campelo, R.

AU - Kim, D.-W.

AU - Bearz, A.

AU - Griesinger, F.

AU - Morabito, A.

AU - Felip, E.

AU - Califano, R.

AU - Ghosh, S.

AU - Spira, A.

AU - Gettinger, S.N.

AU - Tiseo, M.

AU - Gupta, N.

AU - Haney, J.

AU - Kerstein, D.

AU - Popat, S.

N1 - Cited By :15 Export Date: 4 February 2019

PY - 2018

Y1 - 2018

U2 - 10.1056/NEJMoa1810171

DO - 10.1056/NEJMoa1810171

M3 - Articolo

VL - 379

SP - 2027

EP - 2039

JO - New England Journal of Medicine

JF - New England Journal of Medicine

SN - 0028-4793

IS - 21

ER -